Raphael Pharmaceutical (RAPH) Receivables (2024 - 2025)
Raphael Pharmaceutical's (RAPH) quarterly Receivables came in at $2000.0 in Q4 2025, little changed year-over-year from $2000.0 in Q4 2024, and little changed quarter-over-quarter from $2000.0 in Q4 2024.
Powered by 
Analysis
Raphael Pharmaceutical (RAPH) Receivables (2024 - 2025) Analysis & Trends
Raphael Pharmaceutical has disclosed Receivables across 2 years of filings, most recently posting $2000.0 for Q4 2025.
- In Q4 2025, Receivables changed 0.0% year-over-year to $2000.0; the TTM figure through Dec 2025 stood at $2000.0 (changed 0.0% YoY), while the FY2025 annual figure was $2000.0, changed 0.0% from the prior year.
- Receivables came in at $2000.0 for Q4 2025 at Raphael Pharmaceutical, roughly flat from $2000.0 in the prior quarter.
- In the past five years, Receivables ranged from a high of $2000.0 in Q4 2024 to a low of $2000.0 in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 10.23 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 5.90 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 2.13 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 6.57 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 1.93 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 160.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 912.74 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 1.89 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | - |
| 10 | Raphael Pharmaceutical | 28.25 Mn | 28.25 Mn | - | - |